Long-Term Financial Benefits of Drug-Eluting Stents Becoming Evident

Tuesday, April 29, 2008 General News J E 4
NEW YORK, April 28 Each year in the United States alone,almost 1 million people with coronary artery disease are treated with apercutaneous coronary procedure (PCI); worldwide the number is about 2.1million. Up to 50% will experience restenosis -- the re-narrowing of thecoronary artery -- within three to six months. To prevent this, stents aredelivered into the artery during about 70% of PCI procedures.

According to a new report by Kalorama Information, Major World Markets forStents Major World Markets for Stents and the Economics of Drug-ElutingTechnology, the current market for coronary stents in the seven major worldhealthcare markets is $4.9 billion.

Recently, stents have been developed that are covered with drugs beingreleased over time in order to reduce the risk of restenosis caused bycellular proliferation. The market effects of these new drug-eluting stents(DES) began in 2003. Today they represent 69.2% of the total coronary stentmarket, which is expected to grow at a rate of about 4.6% now that the shockthat surrounded the alleged DES problems has dissipated.

"Though drug-eluting stents cost 3 to 4 times as much as bare metalstents, when one examines their cost-effectiveness, the case is clear," notesKalorama analyst Kenneth Krul. "They remain an exciting innovation that willbe a major part of cardiovascular intervention technologies over the next tenyears, and it should become increasingly evident that DES use does in factresult in reduced long-term healthcare costs and improved economic outcomes."

Kalorama Information's report Major World Markets for Stents Major WorldMarkets for Stents and the Economics of Drug-Eluting Technology focuses on themarket applications of current and advanced technologies in the development ofcoronary stents, with an emphasis on drug-eluting stents. The market analysiscovers the seven major world healthcare markets (US, France, Germany, Italy,Japan, Spain and the United Kingdom). Current and future trends, market size,projections, and company profiles are also provided. The report can bepurchased directly from Kalorama Information by visiting

About Kalorama Information

Kalorama Information supplies the latest in independent market research inthe life sciences, as well as a full range of custom research services.Kalorama routinely assists media with healthcare topics, and can provideexperts to speak about markets in the life sciences industry. For moreinformation, contact Andrea Hiller at 212-807-2673, or visit

SOURCE Kalorama Information


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
MannKind Corporation to Hold First Quarter Financi...
Rollins Accounting & Inventory Services, Inc. Appo...